Citations

Clear

2303 citation(s) found for "Yu, Edward".

Abstract WP161: Computational Fluid Dynamics Using SAMMPRIS CT Angiography Quantifies Pro-Atherogenic Shear Stress Linked With Post-Stenotic Flow Vortices
Honda, T , Scalzo, Fabien , Cotsonis, George, Cloft, Harry J. , Zaidat, Osama O. , Chimowitz, Marc I. , Feldmann, Edward, Kaneko, Naoki , Investigators, for the SAMMPRIS, Liebeskind, David S. , Wefers, Daniel, Fiorella, David , Derdeyn, Colin P. , Hinman, Jason D. , Investigators, for the SAMMPRIS

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.wp161 Get It

Background: Low wall shear stress (LSS) is an established cause of pro-atherogenic endothelial pathophysiology, yet it has never been demonstrated in the cerebral circulation affected by intracranial atherosclerotic disease (ICAD). Noninvasive CT angiography (CTA) computational fluid dynamics (CFD) enables high-resolution investigation of detailed post-stenotic phenomena. We used all available CTA data in the SAMMPRIS trial of ICAD to detect and quantify post-stenotic LSS. Methods: CTA source images from SAMMPRIS were reconstructed in 3D followed by geometry refinements to generate a mesh of the diseased arterial lesion and adjacent segments. CFD was performed with Ansys (ICEM, Fluent), applying reference boundary conditions with k-omega turbulence and non-Newtonian modeling of the traversing blood viscosity. 3D CFD parameter maps illustrated velocity, velocity swirling and corresponding wall shear stress. Results: 144 subjects enrolled in SAMMPRIS had CTA at baseline, including 140 with CTA source images enabling CFD. Post-stenotic velocity profiles revealed vortices in all cases, quantified by swirling and turbulent kinetic energy. These luminal flow changes were adjacent to focal regions of LSS in the post-stenotic region (Figure). Conclusions: Low wall shear stress is associated with vortices of fluid flow in CTA CFD modeling of ICAD from SAMMPRIS. CTA source images may be used to noninvasively quantify LSS and model this pro-atherogenic factor in ICAD across a wide variety of lesions. Future studies should examine the related endothelial biology and potential link with plaque evolution.
Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).
Hall, Michael J. , Bodor, J. Nicholas , Xiu, Joanne , Goldberg, Richard M. , Worrilow, William M. , Hwang, Jimmy J., Kim, Edward S. , Lenz, Heinz‐Josef , Shields, Anthony F. , Salem, Mohamed E. , Feldman, Rebecca A. , Grothey, Axel , Raghavan, Derek , Marshall, John L , Korn, Wolfgang Michael

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 505-505

10.1200/jco.2019.37.4_suppl.505 Get It

505 Background: MSI is a tumor biomarker for immunotherapy efficacy that is closely associated w/deficient MMR, and is also variably associated w/somatic muts of the MMR genes, loss of MMR protein expression by immunohistochemistry (IHC), and high TMB. Germ-line muts (Lynch syndrome/LS) in the 4 MMR genes are recognized to have distinct cancer spectrums/penetrance in LS, yet across all tumors, gene-specific variability in MMR IHC, MMR muts, and TMB is understudied. Methods: Results of TGPs performed by Caris Lifesciences (2015-17) were analyzed in colorectal (CRC), endometrial (EC) and all other cancers/tumors (OT) as: 1) all MSI-H tumors (n = 1057) and 2) all tumors w/ ≥1 mut in an MMR gene (n = 470). A subset of cases had IHC for MMR protein and PD-L1 expression. MSI and TMB were determined by NGS. Results: Characteristics of MSI-H tumors and tumors w/ ≥1 MMR mut are seen in the Table. A single MSH6 mut [F1088fs] in a coding microsatellite represented 31% of all MMR muts detected. F1088fs was found in 58% tumors w/MLH1/PMS2 loss (IHC) but only 25% w/MSH2/MSH6 loss (p < 0.001), was more commonly seen in EC vs CRC/OT (p < 0.001), and was negatively associated w/somatic POLE mut (p = 0.002). Distinct mut signatures in the MMR genes (e.g. GLUàSTOP) were seen in tumors w/POLE muts and DNA repair genes. Conclusions: MSI-H and MMR mutated tumors demonstrate marked gene-specific heterogeneity in IHC patterns, TMBs, and somatic muts that may be relevant to treatment selection, resistance, and response. [Table: see text]
Landscape of germline mutations in hepatobiliary carcinoma: Unrealized risk, untapped clinical trial opportunities.
Samadder, Jewel, Rupp, Margaret, Michalski, Scott T. , Lincoln, Stephen E. , Yang, Shan , Nussbaum, Robert L. , Borad, Mitesh J. , Esplin, Edward D.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 236-236

10.1200/jco.2019.37.4_suppl.236 Get It

236 Background: Hepatobiliary cancer (HBC), including cholangiocarcinoma, affects over 40,000 people in the U.S. each year, and results in over 30,000 cancer deaths annually. Despite continuing advances in next-generation sequencing (NGS), the understanding of germline genetic risk as it relates to these malignancies remains limited, and guidelines for the germline testing of these patients are lacking. We report the spectrum of pathogenic/likely pathogenic (P/LP) germline genetic variants observed in patients with HBC, and the clinical utility related to germline genetic test results. Methods: We retrospectively studied a consecutive series of 267 patients referred to Invitae for germline genetic testing based on a personal history of HBC, per an IRB approved protocol. Patients were evaluated with a multigene panel of up to 135 genes chosen by the ordering providers. De-identified clinical and family history information were reviewed as provided by clinicians. Results: Among 267 HBC patients 15% (n = 41) had P/LP variants identified in genes including MUTYH, ATM, CHEK2, BAP1, BRCA1, MLH1, BRCA2, PALB2, TP53, APC, CDH1, MSH6, and PMS2 (12% excluding MUTYH heterozygotes). Amongst patients with a family history (FH) of HBC, P/LP rate was 13%; for patients with a FH of cancers other than HBC, P/LP rate was 16%; for patients with no reported FH, P/LP rate was 13%. Conclusions: In this study, 15% of HBC patients had P/LP variants in cancer-risk genes. The clinical utility of these germline P/LP variants includes 32% of patients who were eligible for ongoing clinical treatment trials based on their germline test results (NCT02286687), 60% with clinical management recommendations per current NCCN guidelines, and cascade testing of at risk family members. These data justify comprehensive germline multigene panel testing in all HBC patients, in view of the potential impact on clinical management for a substantial fraction of positive patients as well as facilitating cascade testing for risk assessment of family members.
P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease
Dulai, Parambir S. , Amiot, Aurélien , Singh, Siddharth , Serrero, Mélanie , Jairath, Vipul , Filippi, Jérôme, Kane, Sunanda V. , Bouhnik, Yoram , Sandborn, William J. , Lasch, Karen, Rosario, Maria , Feagan, Brian G. , Bojic, Daniela, Trang-Poisson, Caroline, Shen, Bo , Altwegg, Romain , Sands, B E, Colombel, J F, Carbonnel, Franck , Bohm, Matthew , Bourrier, Anne, Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Peyrin‐Biroulet, Laurent , Pariente, Benjamin , Loftus, Edward V. , Roblin, Xavier , Buisson, Anthony , Siegel, Corey A , Trang, Caroline , Hudesman, David , Lukin, Dana J.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S316-S316

10.1093/ecco-jcc/jjy222.537 Get It

P435 Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study
D’Haens, Geert , Higgins, Peter , Cataldi, Fabio, Lee, W-J, Huang, B , Vermeire, Séverine , Loftus, Edward V. , Panés, Julián , Panaccione, Remo , Zhou, Wen , Lee, W-J, Xie, Wenhui , Vermeire, Séverine

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S326-S327

10.1093/ecco-jcc/jjy222.559 Get It

Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease
Riley, Charles A. , Marino, Michael J. , Hsieh, Mei‐Chin , Wu, Eric , McCoul, Edward D. , McCoul, Edward D , Wu, Xiao‐Cheng

Mayo Clinic

Head & Neck | January 25, 2019 | Volume: 41 | Issue: 5 | Pages: 1434-1440

10.1002/hed.25600 | PMID 30681216 Get It

AbstractBackgroundAn association is suggested between gastroesophageal reflux disease (GERD) or laryngopharyngeal reflux (LPR) and malignancy of the larynx in elderly patients in the United States. Early detection with flexible fiberoptic laryngoscopy (FFL) or CT remains poorly defined.MethodsThe Surveillance, Epidemiology, and End Results (SEER)‐Medicare linked database was queried from 2003 to 2011.A case‐cohort design evaluated patients aged 66 and older with a diagnosis of GERD and/or LPR for the occurrence of FFL or CT within 6 months of the exposure diagnosis.ResultsOf a total 156 426 Medicare beneficiaries, the relative risk of early cancer diagnosis with FFL was 14.61(95% confidence interval [CI], 13.59‐15.70), corresponding to a number needed to detect (NND) a case of cancer of 13(95% CI, 13‐14). The relative risk of an early cancer diagnosis with CT was 31.83 (95% CI, 29.57‐34.26), with a NND of 5 (95% CI, 5‐5).ConclusionsEarly FFL and CT are associated with a higher likelihood of laryngeal cancer diagnosis in elderly individuals with a diagnosis of reflux. Screening trials are necessary to establish this relationship.
P499 Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2
Sandborn, William J. , Wolf, Douglas C. , Yao, Xinyi , Kisfalvi, Krisztina, Vermeire, Séverine , Loftus, Edward V. , Danese, Silvio , Chen, Jingjing , Vermeire, Séverine

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S361-S362

10.1093/ecco-jcc/jjy222.623 Get It

P258 Abdominal pain and its relationship with clinical outcomes, biomarker levels, and health-related quality of life in patients with moderate to severe ulcerative colitis: data from U-ACHIEVE, a Phase 2b study of upadacitinib
Louis, Édouard , Cataldi, Fabio, Guay, Heath , Lee, W-J, Danese, Silvio , Louis, Edouard , Loftus, Edward V. , Lee, W-J, Ghosh, Subrata

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S226-S226

10.1093/ecco-jcc/jjy222.382 Get It

OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
Vermeire, Séverine , Colombel, J F, Feagan, Brian G. , Sandborn, William J. , D’Haens, Geert , Shafran, Ira, Parfionovas, Andrejus, Rogers, Raquel, Lirio, Richard A. , Vermeire, Séverine , Sands, Bruce E , Danese, Silvio , Panaccione, Remo , Rubin, David T. , Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S018-S020

10.1093/ecco-jcc/jjy222.025 Get It

OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study
Sandborn, William J. , Lee, S D, Hébuterne, Xavier , Cataldi, Fabio, Lacerda, Ana P. , Huang, B , Schreiber, Stefan , Lindsay, James Oliver , Zhou, Wen , Xie, Wenhui , Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S009-S009

10.1093/ecco-jcc/jjy222.013 Get It